SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
223 hedge funds and large institutions have $1.22B invested in SANGAMO THERAPEUTICS INC in 2020 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 69 increasing their positions, 71 reducing their positions, and 26 closing their positions.
81% more call options, than puts
Call options by funds: $40.5M | Put options by funds: $22.4M
58% more capital invested
Capital invested by funds: $772M → $1.22B (+$450M)
54% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 26
6% more funds holding
Funds holding: 210 → 223 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 71
2.55% less ownership
Funds ownership: 57.9% → 55.35% (-2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$34.7M |
| 2 |
JP Morgan Chase
New York
|
+$9.41M |
| 3 |
Goldman Sachs
New York
|
+$7.42M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$6.9M |
| 5 |
Morgan Stanley
New York
|
+$5.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$36.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.67M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.59M |
SGMO Hedge Fund Activity: Q4 2020 in Review
223 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2020, worth a combined $1.22B — up 58% from $772M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SGMO positions and 26 closed out — a net gain of 14 holders — while 69 added to existing stakes and 71 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $34.7M. The largest seller was Bellevue Group, exiting entirely with an estimated $36.4M sold.
- 223 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2020, up from 210 in Q3 2020.
- Funds reported $1.22B of SANGAMO THERAPEUTICS INC stock for Q4 2020, up 58% quarter-over-quarter.
- 40 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2020 and 26 closed out, a net change of +14 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2020 was Wasatch Advisors, an estimated $34.7M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2020 was Bellevue Group, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2020.